GWP-42006 is under clinical development by Jazz Pharmaceuticals and currently in Phase II for Partial Seizure. According to GlobalData, Phase II drugs for Partial Seizure have an 86% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how GWP-42006’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GWP-42006 (CBDV, cannabidivarin) is under development for the treatment of focal seizure (epilepsy), autism spectrum disorders, Rett syndrome, fragile X syndrome, and HIV associated neuropathic pain. It is administered orally as a solution. The drug candidate is a cannabinoid.
Jazz Pharmaceuticals overview
Jazz Pharmaceuticals is a specialty biopharmaceutical company which identifies, develops, and commercializes medicines with focus on narcolepsy, cancer, pain, and psychiatry. Its marketed products include Xyrem (sodium oxybate) oral solution, Sunosi (solriamfetol), Defitelio (defibrotide sodium), Erwinaze (asparaginase erwinia chrysanthemi), Vyxeos (daunorubicin and cytarabine) liposome for injection, and others. The company also has various pipeline product candidates related to focus areas such as sleep, neurological disorders, hematology, and oncology including hematologic malignancies and solid tumors. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.
For a complete picture of GWP-42006’s drug-specific PTSR and LoA scores, buy the report here.